Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Direct R&D by Quarter
Direct R&D — Other Clinical Product Candidates & Earlier-Stage Research Programs ($M) ($M)
Regeneron Pharmaceuticals Direct R&D: $263M in Q3 2026, up 23.1% from a year earlier. That is the highest of the 39 quarters on record here.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Other product candidates in clinical development and other research programs | 263.0 | 213.7 | 49.3 | 696.7 | 597.4 | 99.3”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up direct R&D
- Direct Clinical R&D — REGEN-COV (casirivimab & imdevimab) [legacy FY20–FY23] ($M)7 · Q4 2022
- Direct Clinical R&D — EYLEA (2 mg) [legacy through FY22] ($M)16.3 · Q2 2022
- Direct Clinical R&D — Fasinumab (anti-NGF antibody) [legacy through FY21] ($M)9.40 · Q4 2021
- Direct Clinical R&D — Evkeeza (evinacumab) [legacy through FY20] ($M)7 · Q4 2020
- Direct Clinical R&D — Praluent (alirocumab) [legacy through Q1 2020] ($M)13.5 · Q1 2020
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Direct R&D ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-other
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?